Ignite Creation Date:
2024-05-05 @ 11:39 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00098358
Status:
UNKNOWN
Last Update Posted:
2007-02-07
First Post:
2004-12-07
Brief Title:
Study of Oral Zileuton in the Treatment of Moderate to Severe Facial Acne Vulgaris
Sponsor:
Critical Therapeutics
Organization:
Critical Therapeutics
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled Parallel-Group Multicenter Clinical Proof of Concept Study of Zileuton IR in Patients With Moderate to Severe Facial Acne Vulgaris
Status:
UNKNOWN
Status Verified Date:
2007-02
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Tissue inflammation is a major component of the acne disease process Leukotriene B4 LTB4 is thought to be a major player in the development of tissue inflammation Synthesis of LTB4 is controlled by the enzyme 5-lipoxygenase Zileuton blocks the activity of 5-lipoxygenase This study will test the safety and efficacy of zileuton in the treatment of facial acne
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None